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Ovarian cancer is the fourth most common cancer diagnosed
among Canadian women. Approximately 2500 women (14.0 per
100 000) will be diagnosed with ovarian cancer and 1400 will die
from this disease in 1998 (National Cancer Institute of Canada,
1998). In Canada, the incidence rate of ovarian cancer has
declined slightly over the past two decades; however, age-specific
incidence rates show different patterns (On and Semenciw, 1995).
The aetiologies of ovarian cancers, especially of non-epithelial
ovarian tumours (germ cell and sex cord-stromal) are poorly
understood. Previous epidemiological studies have focused on
aetiologies of epithelial tumours (serous, mucinous, endometrioid,
clear cell, etc.) (Whittemore et al, 1992). Several factors including
advanced age (Ewertz and Kjaer, 1988), nulliparity (Mosgaard
et al, 1997) and a family history of ovarian cancer (Amos and
Struewing, 1993) have been consistently associated with an
increased risk of epithelial ovarian cancer, while other factors such
as number of full-term pregnancies (Risch et al, 1994a), oral
contraceptive (OC) use (Rosenberg et al, 1994) and history of
hysterectomy or tubal ligation (Hankinson et al, 1993) have been
consistently associated with a decreased risk. Evidence regarding
the roles of other factors, including age at menarche/menopause
and age at first childbirth (Negri et al, 1991), hormone replace-
ment therapy (HRT) (Hempling et al, 1997), infertility and fertility
drug use (Risch et al, 1994a), breastfeeding (Siskind et al, 1997),
obesity (Farrow et al, 1989), diet (Risch et al, 1994b), talc use
(Chang and Risch, 1997), smoking and alcohol or coffee
consumption (Whittemore et al, 1988), is inconclusive.
On the other hand, few studies have focused on aetiologies on
non-epithelial ovarian tumours. Walker et al (1988) observed an
elevated risk of germ cell ovarian cancer among girls and young
women, the mothers of whom were under 20 years of age at time
of pregnancy, had used exogenous hormones during the pregnancy
or had a high pre-pregnancy body mass. Use of oral contraceptives
was associated with an increased risk of germ cell tumours (Horn-
Ross et al, 1992). However, a history of oral contraceptives use or
oestrogen replacement therapy was associated with a decreased
risk of developing sex cord-stromal ovarian tumours.
Cohort effects are reported to have an important impact on
ovarian cancer incidence time trends. An earlier study in Denmark
reports a remarkable increasing risk of ovarian cancer for cohorts
of women born between 1863 and 1898 and the risk stabilized for
cohorts born thereafter (Ewertz and Kjaer, 1988). Significant
cohort effects on ovarian cancer incidence trends have also been
observed in Sweden, England/Wales and Norway (Adami et al,
1990; Dos Santos Silva and Swerdlow, 1995; Bjorge et al, 1997).
These studies generally found that the risk of developing ovarian
cancer increased sharply among women born during the last
decades of the nineteenth century, and the risk increased slowly
among women born during the first decades of the twentieth
century and declined for cohorts born in recent decades.
Although reports on incidence trends are available for ovarian
cancer overall, reports on histology-specific trends are sparse
(Cramer et al, 1981; Farrow and Rosenblatt, 1996). The purpose of
this study is to investigate ovarian cancer incidence trends
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according to histology subtype and to study the impact of age,
period and cohort effects on these trends in Canada during the time
period 1969—1993.
MATERIALS AND METHODS
Data source
Ovarian cancer incidence data including histology-specific data
were obtained from provincial cancer registries through the
Canadian Cancer Registry (CCR) at Statistics Canada for the study
period 1969 to 1993. Annual population estimates were obtained
from the Demography Division of Statistics Canada for the same
period. Since histology-specific data were available for the full
study period only for provinces of British Columbia, Ontario and
Saskatchewan, this study was based on data obtained from these
three provinces only.
British Columbia and Saskatchewan were the first two
provinces in Canada to have cancer registries (Health and Welfare
Canada, 1993); by 1935 the two provinces had established popula-
tion-based cancer registries. By 1965 Ontario had also built a
population-based cancer registry. The provincial cancer registries
obtain cancer incidence information from various sources
including patient diagnosis and treatment records, pathology
reports, hospital separation records, death certificates and autopsy
reports. In these three provinces, the proportion of microscopically
confirmed ovarian tumours remained 87—90% and the proportion
of cases identified by death certificate only (DCO) stayed 2—3%
during the study period.
Ovarian cancer, defined as a malignant neoplasm of the ovary,
was coded as 183.0 in the 8th (1969—1978) and 9th (1979—1993)
revisions of the International Classification of Diseases (ICD-8,
ICD-9) (WHO, 1977). ￿Borderline￿ ovarian tumours were
excluded in the analysis. Histology subtypes were identified using
the International Classification of Diseases for Oncology (ICDO)
(WHO, 1976; Berg, 1982). Major subtypes included serous
tumours (ICDO 8441, 8442, 8460, 8461, 8462), mucinous
tumours (ICDO 8470, 8471, 8472, 8473, 8480, 8481),
endometrioid tumours (ICDO 8380, 8381, 8560), clear cell
tumours (ICDO 8310), germ cell tumours (ICDO 906—910), sex
cord-stromal (ICDO 859—867), all other classified epithelial
ovarian tumours (ICDO 8010, 8021, 8050, 8140, 8260, 8440,
8450, 8570, 8950, 8951, 8980, 9110, etc.) and NOS (not otherwise
specified)/unclassified tumours (ICDO 800 and 999).
Statistical analysis
Annual age-standardized incidence rates (ASIRs per 100 000
women) for ovarian cancer and its histology subtypes were
calculated for 1969—1993 by the direct method, using the 1991
Canadian census population as standard. Histology-specific
temporal trends of the ASIRs were studied using average annual
per cent change (AAPC), approximated with logarithm regression
coefficients and tested by t-tests (National Cancer Institute of
Canada, 1998).
Age-specific incidence rates (per 100 000 women) for each
histology subtype were calculated according to age group (0—4,
￿, 80—84, 85+) for the period 1989—1993.
To study the impact of calendar period and birth cohort on
histology-specific incidence trends of ovarian cancer, log-linear
regression models were applied assuming that the observed
number of cancer cases followed a Poisson distribution. Several
models were used: full model (APC) including three factors, age
(A), calendar period (P) and birth cohort (C); two-factor models
consisting of age and period (AP) or age and cohort (AC); and
one-factor models including age (A) or age-drift (AD) in which
the period is treated as a continuous variable (Clayton and
Schifflers, 1987a, 1987b). The SAS procedure GENMOD (SAS
Institute Inc., 1996) was used to compute parameter estimates for
age, period and cohort.
For each histology-specific subtype, various models including
A, AD, AP, AC and APC were fitted. Goodness-of-fit of the
various models and the overall significance of age, cohort, or
period effect were tested using log-likelihood test by means of the
scaled deviance. A suggested best model was determined for each
of the histology subtypes based on model fit. The best model indi-
cates the best statistical approach to describe the impact of age,
period and cohort effects on a specific incidence time trend. For
example, the best model APC means that age, period, cohort are
all significantly associated with the incidence trend, while AC
indicates that only age and cohort are significantly related to the
incidence trend. Parameter estimates were computed through the
best model and the significance of these estimates was tested using
the c2 test.
Due to the linear relationship between age, period and cohort,
parameter estimates of birth cohorts cannot be unequivocally iden-
tified and a constraint must be applied. In this study, the parame-
ters were estimated under the constraint that the effects for the
first and the last birth cohorts were equal to zero. Since different
constraints may result in different sets of parameter estimates, the
magnitude of the parameter estimates cannot be interpreted using
relative risk (RR) and 95% confidence interval (CI). However,
remarkable changes in the direction of birth cohort or time period
effects remain the same under different constraints (Tarone and
Chu, 1996). In general, these direction changes may suggest mean-
ingful impacts of period and/or cohort effects on incidence trends.
For example, a notable change in the direction of birth cohort
effect may suggest an increasing or decreasing exposure to a risk
factor among that birth cohort. A sharp change in the direction of
period effect may indicate an improved data capture process in
cancer registries, an enhanced cancer diagnosis method, introduc-
tion of an efficient screening test, or changes to a more recent
histological classification.
For analyses of overall ovarian cancer and all subtypes except
germ cell tumours, the data were organized into twelve 5-year age
groups (25—29, 30—34, ￿, 80—84), five 5-year time periods
(1969—1973, ￿, 1989—1993) and seventeen overlapping 10-year
birth cohorts (1884—1993, 1889—1998, ￿, 1959—1968). Each birth
cohort was identified by the 7th year of the interval (i.e. 1890,
1895, ￿, 1965). For example, the 1895 birth cohort represents
women born from 1889 through 1898, about 50% of these born
between 1891 and 1895. Note that the 1895 birth cohort overlaps
both with the 1890 and the 1900 birth cohort by 25%. For analysis
of germ cell tumours, the data were organized into fourteen 5-year
age groups (0—4, 5—9, ￿, 65—69), five 5-year time periods and
eighteen overlapping 10-year birth cohorts (1905, 1910, ￿, 1990).
RESULTS
During the study period 1969—1993, 23 289 ovarian cancer cases
were identified in the provinces of British Columbia, Ontario and
Saskatchewan. Serous tumours accounted for 24.2% (n = 5645),154 J Zhang et al
British Journal of Cancer (1999) 81(1), 152–158 © Cancer Research Campaign 1999
followed by mucinous tumours 11.0% (n = 2565), endometrioid
tumours 7.1% (n = 1650), clear cell tumours 2.4% (n = 552), germ
cell tumours 2.3% (n = 546) and sex cord-stromal 1.8% (n = 409).
In addition, other classified epithelial ovarian tumours accounted
for 39.8% (n = 9258) and NOS/unclassified tumours 11.4%
(n = 2664) of all ovarian cancer cases.
ASIRs and AAPC for ovarian cancer histology subtypes for the
period 1969—1993 are displayed in Table 1. The overall incidence
rate of ovarian cancer dropped slightly over the time period.
However, incidence rates according to histology subtypes showed
different patterns. On one hand, a substantial increase in incidence
rates was seen for serous tumours, endometrioid tumours, clear
cell tumours and germ cell tumours, with an average annual
percentage change of 5.4%, 8.4%, 11.2% and 2.0% respectively.
On the other hand, incidence rates of sex cord-stromal and other
classified epithelial ovarian tumours declined considerably with an
average annual percentage change of 3.9% and 4.8%. No signifi-
cant increase or decrease in incidence rates was observed for
mucinous and NOS/unclassified tumours during the study period
(P > 0.05).
The age-specific incidence rates of ovarian cancer overall
increased exponentially with age, peaking at ages 75—84 (53.97
per 100 000 women) and decreasing slightly after age 85. Figure 1
displays the age-specific incidence rates by histology subtype for
the period 1989—1993. Incidence rates of serous, mucinous and
endometrioid tumours rose with age, peaking at 70—74 for serous
tumours (18.53) and endometrioid tumours (4.57), and at 75—79
for mucinous tumours (5.14). A similar age-specific incidence
pattern was seen for clear cell tumours and sex cord-stromal
tumours. The incidence rate increased quickly after middle-age
and peaked at ages of 55—59 for clear cell (2.24) and sex
cord-stromal tumours (0.79). However, a different age-specific
Table 1 Age-standardized incidence (per 100 000 women) and average
annual percentage change (AAPC) by ovarian cancer histology-specific
subtype, Ontario, British Columbia and Saskatchewan, 1969–1993
Ovarian cancer Incidence Incidence AAPC (%)
histology subtypes 1969–1971 1991–1993 1969–1993
All ovarian cancer 14.56 13.71 –0.5a
Serous 1.45 4.61 +5.4a
Mucinous 1.24 1.72 +0.71
Endometrioid 0.18 1.28 +8.4a
Clear cell 0.08 0.60 +11.2a
Sex cord-stromal 0.40 0.16 –3.9a
Germ cell 0.21 0.47 +2.0b
Other classified epithelial 9.82 3.57 –4.8a
NOS/unclassified 1.19 1.29 –0.2
aP < 0.01; bP < 0.05.
Table 2 Best log-linear models and model fit for ovarian cancer incidence
by histology-specific subtype
Ovarian cancer Log-linear modela df Model fit P-value
histology subtypes deviance
All ovarian cancer Age-cohort 33 30.36 0.60
Serous Age-period-cohort 30 29.78 0.50
Mucinous Age 48 64.42 0.06
Endometrioid Age-period-cohort 30 33.54 0.30
Clear cell Age-period 43 54.02 0.12
Sex cord-stromal Age-drift 47 59.78 0.10
Germ cell Age-cohort 42 53.61 0.11
Other classified epithelial Age-period-cohort 30 40.94 0.09
NOS/unclassified Age-period 44 70.48 0.01
aBest model for each histology subtype
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incidence pattern was observed for germ cell tumours. The inci-
dence rate was generally high among children, peaking at age
15—19 (1.02) and declining thereafter.
Table 2 presents the best models for each subtype according
to model fit and log-likelihood test. Age was found to have a
significant impact on each of the ovarian cancer histology-specific
incidence time trends. However, cohort and period have signifi-
cant impacts on some histology subtypes but not on others.
A strong cohort effect was observed with the incidence trend
of ovarian cancer overall but no significant period effect was
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detected. A rapidly increasing overall risk of ovarian cancer was
seen among birth cohorts from 1890 to 1920. The risk, however,
decreased consistently among women in the birth cohorts from
1925 to 1950 and appeared to level off in cohorts from 1955 to
1960. No cohort effect was observed for the incidence trend of
NOS/unclassified tumours. The incidence trend of this subtype
appears to be directly affected by the period effect.
Neither cohort effect nor period effect was detected in the
incidence rates of mucinous tumours over the study period. In
contrast, both cohort and period effect had significant impacts on
the increasing incidence rates of serous and endometrioid tumours
and decreasing incidence rates of other classified epithelial ovarian
tumours. Figure 2 displays the significant cohort effects for epithe-
lial ovarian tumours. An elevated risk of serous tumours among
birth cohorts of 1895—1930 was observed. The risk decreased
slightly among cohorts of 1930—1945 and dropped quickly in the
younger cohorts of 1950—1960. The risk of endometrioid tumours
appeared to be relatively stable between cohorts of 1905 and 1935;
the risk dropped among cohorts of 1935—1940, but increased in
younger cohorts 1950—1960. The cohort effect on the incidence
trend of other classified epithelial ovarian tumours is the same as
for ovarian cancer overall. However, the cohort effect on the inci-
dence trend of clear cell tumours is not statistically significant.
The increase in incidence rates of serous and endometrioid
tumours can also be partially explained by increasing period
effects between 1969 and 1988 (data not shown) in addition to the
cohort effect. Similarly, the significant decrease in incidence rates
of other classified epithelial ovarian tumours is also influenced by
a consistent decreasing period effect (data not shown). However,
the dramatic increase in incidence rates of clear cell tumours
appeared to be explained by an increasing period effect alone.
The increase in incidence rates of germ cell tumours was mainly
influenced by cohort effect (Figure 3). In spite of variation due to
the small number of cancer cases, a constant and significant
increasing risk of germ cell tumours was observed in younger
cohorts of 1965—1980. The declining incidence rate of sex cord-
stromal ovarian cancer can be explained by both cohort effect and
period effect. The risk dropped constantly for birth cohorts from
the 1910 birth cohort to the 1950 cohort and increased slightly in
the 1960 cohort (Figure 3). A consistent decreasing period effect
over the study period was also evident (data not shown).
DISCUSSION
Age-period-cohort analysis allows us to characterize the impacts
of age, period and cohort on incidence time trends. However, limi-
tations regarding this statistical methodology have been reported
and interpretation of results from age-period-cohort analyses
should be made with caution (Clayton and Schifflers, 1987b;
Tarone and Chu, 1996). First of all, misclassification bias may be
involved due to the notable overlap of birth cohorts. Second, inter-
pretation of an age-period model requires taking into account the
possibility that a period effect may occur when a change in expo-
sure to a carcinogen affects all age groups equally. Third, the inter-
pretation of an age-cohort model needs to consider the likelihood
that a cohort effect may arise when there is a strong interaction
between exposure and age group even if all age group exposed in a
particular period were affected.
The relative completeness of histology-specific data in the three
provincial cancer registries over the 25-year period provides a
unique opportunity to examine histology-specific incidence trends
of ovarian cancer. In our data, however, the proportions of serous,
endometrioid and clear cell tumours were lower and the propor-
tions of NOS/unclassified (11.4%) and other classified epithelial
ovarian tumours (39.8%) were higher than those reported else-
where (Koper et al, 1996; Bjorge et al, 1997), suggesting potential
data quality concerns. The proportion of NOS/unclassified ovarian
tumours remained about 11% over the study period; however, the
proportion of all other classified epithelial ovarian tumours
dropped sharply from approximately 60% to 23% during the study
period. Ovarian cancer can be difficult to diagnose: in particular,
determination of histology-specific subtypes is considerably
inconsistent among pathologists. In addition, the criteria for
histology classification of ovarian tumours changed over the study
period. Thus diagnostic bias may be involved in this study,
although the impact of this bias on the cohort effects estimated in
this study is unclear. The histology-specific incidence rates for
serous, endometrioid, clear cell tumours might be underestimated
and the rates for all other epithelial ovarian tumours might be over-
estimated for the early study period. In age-period-cohort analysis,
the changes of histology classification criteria over the study
period would be mainly reflected in the period effect.
Over the study period 1969—1993, the age-standardized inci-
dence rates for overall ovarian cancer dropped slightly. However,
the rates of serous, endometrioid, clear cell and germ cell tumours
increased significantly and the rates of sex cord-stromal and other
classified epithelial ovarian tumours decreased considerably. The
rates of mucinous and NOS/unclassified tumours remained
unchanged. A direct comparison cannot be made because few
epidemiological studies have reported histology-specific incidence
trends for ovarian cancer (Cramer et al, 1981; Farrow and
Rosenblatt, 1996).
The age-specific incidence rates by histology subtype observed
in this study showed patterns similar to those reported in previous
studies based on data from the US Third National Cancer Survey
(Weiss et al, 1977), the Danish Cancer Registry (Ewertz et al,
1988) and the Vaud Cancer Registry in Switzerland (Levi et al,
1993).
Period effect
For ovarian cancer overall, no period effect on the incidence time
trend was observed, indicating no significant changes in cancer
registry data capture procedures, no significant improvement in
cancer diagnosis methods and no screening tests introduced during
the study period. However, substantial increasing period effects
were seen for serous, endometrioid and clear cell tumours and a
dramatic decreasing period effect was observed for all other classi-
fied epithelial ovarian tumours. Decreasing period effects were
also seen for sex cord-stromal and NOS/unclassified ovarian
tumours. These opposite period impacts suggest changes in
ovarian cancer histology diagnosis criteria. For example, improve-
ments of histology classification criteria for serous, endometrioid
and clear cell tumours may have resulted in decreasing rates of
other classified epithelial ovarian tumours. The histology classifi-
cation appears to remain unchanged for mucinous and germ cell
tumours as no period effects were evident for these two subtypes.
Cohort effect
Previous studies have suggested that epithelial and non-epithelial
ovarian tumours have different aetiologies (Horn-Ross et al, 1992;Histology-specific incidence trends of ovarian cancer 157
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Albrektsen et al, 1997). In addition, the aetiology of mucinous
tumours is reported to be different from other epithelial tumours
(Risch et al, 1996). An observation of significant cohort effects for
incidence trends of serous and endometrioid tumours but not for
trend of mucinous tumours appears to support Risch￿s hypothesis.
The cohort impact on incidence trends of serous and all other
epithelial ovarian tumours may be closely associated with child-
bearing patterns. For example, the increasing risk for birth cohorts
around the turn of the century may be related to a substantial
decline in parity among grandmothers of babies born in ￿boom
years￿ (Whittemore et al, 1992). Other factors such as increased fat
intake and talc use may also contribute to the increasing risk (Risch
et al, 1994b; Chang and Risch, 1997). On the other hand, the
slightly decreasing risk in the 1930—1945 cohorts may be related to
an increasing parity among mothers of the babies born in boom
years. Data from Statistics Canada (1993) show that the crude birth
rate (per 1000 population) decreased consistently from 45.0 to 20.6
in the period of 1860—1939 and the rate increased from 20.6 in
1939 to 28.2 in 1957 and stayed relatively high until 1964.
Oral contraceptive use and hysterectomy/tubal ligation may
also play a role in the cohort effects observed for serous and
endometrioid tumours. OC use and a history of hysterectomy/tubal
ligation reduces the risk of ovarian cancer by half (Hankinson
et al, 1993; Rosenberg et al, 1994). These two factors may be
responsible for the decreasing risk of serous tumours among the
younger cohorts of 1950—1960. Although data on OC use before
1977 are not available, data obtained from Saskatchewan Drug
Plan (Saskatchewan Health Department, 1998) show a constant
high prevalence of OC use among young women aged 15—29
(35%) from 1977 to 1992. The apparent increasing risk of
endometrioid tumours among young cohorts of 1950—1960 is
harder to explain. Hysterectomy and tubal ligations are reported to
have specific strong protective effects for endometrioid tumours
(Rosenblatt and Thomas, 1996). We found that incidence rates of
hysterectomy and tubal ligations in Canada have declined since
1971 (Zhang, 1998), which may have influenced the slightly
elevated risk of endometrioid tumours. To confirm this hypothesis,
more studies are needed.
A few studies have investigated aetiologies of germ cell
tumours (Walker et al, 1988; Horn-Ross et al, 1992). Since most
germ cell tumours occur among girls and young women, causal
factors may occur early in life, possibly even in utero. Similarly, a
significant increasing risk of testicular germ cell tumours among
boys and young men is reported in Canada (Liu et al, 1998).
Perinatal factors including mother￿s exposure to exogenous
oestrogen during the pregnancy and high pregnancy body weight
have been associated with an increased risk. In addition, use of
oral contraceptives is associated with an increased risk of germ
cell tumours, but the role of parity is unclear (Horn-Ross et al,
1992; Adami et al, 1994; Albrektsen et al, 1997). Our study
suggests that young women born in recent decades have experi-
enced a higher risk of developing germ cell ovarian cancer. Further
studies to examine the associations between hormonal exposure
during pregnancy and OC use and the risk of developing germ cell
ovarian tumours are warranted.
The aetiology of sex cord-stromal ovarian tumours is poorly
understood. The evidence regarding the effect of parity on sex
cord-stromal risk is controversial (Horn-Ross et al, 1992; Adami et
al, 1994; Albrektsen et al, 1997). However, a history of using oral
contraceptives or hormone replacement therapy (HRT) was associ-
ated with a decreased risk of developing sex cord-stromal ovarian
tumours and a history of hysterectomy or tubal ligation did not
affect the risk (Horn-Ross et al, 1992). In our study, we observed
that women born in the 1910—1955 cohorts had a constant
decreasing risk of developing sex cord-stromal ovarian tumours.
This finding may be related to an increasing prevalence of HRT
among Canadian women aged 45—59 from 15% in 1977 to 25% in
1996 (Saskatchewan Health Department, 1998). The hypothesis
that OC use or HRT may reduce the risk of developing sex cord-
stromal ovarian tumours needs to be confirmed in analytic
epidemiological studies.
In summary, the different cohort patterns by histology subtype
suggest that ovarian cancer is not a single disease and involves
different aetiologies. In particular, the aetiologies of mucinous,
germ cell and sex cord-stromal tumours are different and poorly
understood; studies are warranted in this area. Further epidemio-
logical studies examining ovarian cancer histology-specific inci-
dence rates should also take into consideration the changes
in classification criteria.
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